http://orcid.org/0000-0002-8476-6702
References
- Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505–2515.
- Cullen WR. Chemical mechanism of arsenic biomethylation. Chem Res Toxicol. 2014;27(4):457–461.
- Rehman K, Naranmandura H. Arsenic metabolism and thioarsenicals. Metallomics. 2012;4(9):881–892.
- Chen GQ, Zhou L, Styblo M, et al. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res. 2003;63(8):1853–1859.
- Chen B, Lu X, Shen S, et al. Arsenic speciation in the blood of arsenite-treated F344 rats. Chem Res Toxicol. 2013;26(6):952–962.
- Yoshino Y, Yuan B, Miyashita SI, et al. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Anal Bioanal Chem. 2009;393(2):689–697.
- Iriyama N, Yoshino Y, Yuan B, et al. Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient. J Hematol Oncol. 2012;5(1):1–11.
- Moe B, Peng H, Lu X, et al. Comparative cytotoxicity of fourteen trivalent and pentavalent arsenic species determined using real-time cell sensing. J Environ Sci-China. 2016;49:113–124.
- Guo M, Wang W, Hai X, et al. HPLC-HG-AFS determination of arsenic species in acute promyelocytic leukemia (APL) plasma and blood cells. J Pharmaceut Biomed. 2017;145:356–363.
- Chunlu G, Hu S, Guo M, et al. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia. Cancer Chemoth Pharm. 2018;82(2):229–236.
- Fujisawa S, Ohno R, Shigeno K, et al. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer Chemoth Pharm. 2007;59(4):485–493.
- Šlejkovec Z, Podgornik H, Černelč P, et al. Exceptions in patterns of arsenic compounds in urine of acute promyelocytic leukaemia patients treated with As2O3. Biometals. 2016;29(1):107–118.
- Chen B, Cao F, Yuan C, et al. Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Anal Bioanal Chem. 2013;405(6):1903–1911.
- Ito K, Palmer CD, Steuerwald AJ, et al. Determination of five arsenic species in whole blood by liquid chromatography coupled with inductively coupled plasma mass spectrometry. J Anal Atom Spectrom. 2010;25(8):1334–1342.
- Csanaky I, Németi B, Gregus Z. Dose-dependent biotransformation of arsenite in rats-not S-adenosylmethionine depletion impairs arsenic methylation at high dose. Toxicology. 2003;183:77–91.
- Lu M, Wang H, Li XF, et al. Evidence of hemoglobin binding to arsenic as a basis for the accumulation of arsenic in rat blood. Chem Res Toxicol. 2004;17(12):1733–1742.
- Lu M, Wang H, Li XF, et al. Binding of dimethylarsinous acid to cys-13α of rat hemoglobin is responsible for the retention of arsenic in rat blood. Chem Res Toxicol. 2007;20(1):27–37.
- Mondal B, Chatterjee D, Bhattacharyya M. Structure-function alteration of hemoglobin in arsenicosis patients: a probable pathway to exert toxicity. J Appl Toxicol. 2012;32(8):581–589.
- Naranmandura H, Suzuki KT. Identification of the major arsenic-binding protein in rat plasma as the ternary dimethylarsinous-hemoglobin-haptoglobin complex. Chem Res Toxicol. 2008;21(3):678–685.
- Mandal BK, Ogra Y, Anzai K, et al. Speciation of arsenic in biological samples. Toxicol Appl Pharm. 2004;198(3):307–318.
- Styblo M, Del Razo LM, Vega L, et al. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol. 2000;74(6):289–299.